Latest news
Silence Therapeutics Plans Underwriters' Option: Up to 15% More Depositary Shares - Stock TitanStock Titan · Mon, 10 Aug 2026 20:01:00 GMTThere are notable gap-ups and gap-downs in today's session. - ChartMillChartMill · Mon, 10 Aug 2026 14:30:00 GMTSilence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 14:00:27 GMTDivesiran Meets Primary Response End Point in Phlebotomy-Dependent Polycythemia Vera - OncLiveOncLive · Mon, 10 Aug 2026 12:41:31 GMTSilence announces results from Phase 2 SANRECO trial met primary endpoint - TipRanksTipRanks · Mon, 10 Aug 2026 11:41:31 GMTSilence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:30:00 GMTSilence Therapeutics (SLN) halves net loss and boosts cash in Q2 2026 - Stock TitanStock Titan · Mon, 10 Aug 2026 11:20:49 GMTRactigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 11:56:14 GMT